G-protein-coupled receptors (GPCR) are transmembrane proteins involved in various physiological and pathophysiological processes and signalling pathways. Due to their key role, they have been in the focus of science and industry for the past decades to search for new diagnostic markers and pharmaceuticals for the treatment of various diseases. Already around 30% of the therapeutic drugs approved in the USA act upon GPCRs, and their number is constantly rising. For several years GPCRs have also been increasingly investigated in connection with autoimmunity (for an overview, see Review from Cabral-Marques and Riemekasten, Nature Reviews Rheumatology 2017).
The 2nd Symposium on Regulatory Autoantibodies Targeting G-Protein-Coupled Receptors, taking place from 28th to 30th September 2018, gives insights into the role of these receptors in autoimmune diseases. Internationally renowned scientists from the fields of autoimmune diagnostics and GPCR research, such as Prof. Dr. Gabriela Riemekasten (Luebeck, Germany), Prof. Dr. Yehuda Shoenfeld (Tel Aviv, Israel) and Prof. Dr. Martin Lohse (Berlin, Germany) will discuss the chances, obstacles and the future of anti-GPCR antibodies as a marker and therapeutic agent in various diseases.
For further information on the symposium and registration, please refer to https://www.rab-symposium.org/. Abstracts can be submitted until 20th August 2018.
We look forward to seeing you at the EUROIMMUN booth.